Latest Breaking News On - Wyss founding director donald ingber - Page 1 : comparemela.com

CAR-T cell therapies are transforming the treatment of previously incurable blood cancers, but a large proportion of patients still responds only poorly or not at all to them, calling for new strategies to overcome this challenge. Now, a research team has developed a simple intervention in the form of a biodegradable scaffold material called T-cell enhancing scaffolds (TES) that can be locally injected under the skin and used to restimulate CAR-T cells after their administration. This increased their therapeutic efficacy and significantly curbed tumor growth and prolonged animal survival in an aggressive mouse lymphoma model.

United statesMiguel sobralRobertp pinkasYoav binenbaumYutong liuDonald ingberDave mooneyDavid mooneyDavid zhangJoshua brockmanKwasi adu berchieDrug administrationHarvard johna paulson school of engineeringWyss institute at harvard universityNational institutes of healthUniversity of wisconsin